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ABSTRACT
The metabotropic glutamate receptor 5 (mGluR5) is a GPCR coupled to the
heterotrimeric G protein Gαq/11 and activates signaling pathways important for excitatory
synaptic transmission. Emerging studies reveal that Amyloid β (Aβ) acts as an
extracellular scaffold for mGluR5. We have identified Ca2+/Calmodulin-dependent
protein Kinase IIα (CaMKIIα) as an interacting protein of mGluR5. We hypothesize that
CaMKIIα plays a role in mGluR5 signaling and Aβ produces differential effects on the
regulation of mGluR5 by CaMKIIα.

We find that overexpression of CaMKIIα

significantly impairs mGluR5-mediated ERK1/2 phosphorylation but does not effect
inositol phosphate formation or Ca2+ release. We find that Αβ increases the amount of
co-immunoprecipitated CaMKIIα to mGluR5 and can activate mGluR5-mediated
ERK1/2 phosphorylation via a PKC-dependent mechanism. mGluR5 and CaMKIIα are
involved in learning and memory. Furthermore, Aβ and mGluR5 are implicated in
Alzheimer’s disease. Thus, investigating how these proteins work together could provide
insight for developing treatments for Alzheimer’s disease.
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CHAPTER 1
INTRODUCTION
1.1 G protein-coupled receptors
G protein-coupled receptors (GPCRs) make up the largest family of
transmembrane receptors that function to transduce extracellular signals into intracellular
responses (Lagerstrom and Schioth, 2008).

GPCRs are composed of seven

transmembrane domains and can be activated by a variety of stimuli including photons,
odorants, hormones, amino acids, peptides and neurotransmitters (Hoon et al, 1999).
Activation of GPCRs by agonist binding induces a conformational change in the receptor
that allows GDP to be exchanged for GTP on the α subunit of the heterotrimeric GTPbinding protein (G protein), subsequently leading to the disassociation of the α subunit
from the receptor and the Gβγ subunit. These subunits activate or inhibit a variety of
signaling pathways in order to modulate cellular functions (Neer, 1995). Factors affecting
GPCR regulation have been studied intensively since they regulate many physiological
functions and their dysregulation contributes to the development of many disease states.
Furthermore, it is estimated that over 40% of all pharmaceutical drugs target GPCRs or
their downstream effectors making them a prime target for the development of novel
therapeutic agents (Zhang and Xie, 2012).
GPCRs are classified into three main groups based on sequence homology. Class
A includes the rhodopsin-like receptors, Class B includes the secretin/glucagon receptors,
and Class C includes a unique member of GPCRs known as the metabotropic glutamate
receptors (Lagerstrom and Schioth, 2008). The focus of this thesis will be on the
metabotropic glutamate receptors.
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1.2 Group I Metabotropic Glutamate Receptors
Glutamate is the major excitatory neurotransmitter in the central nervous system.
It exerts its effects by activating two distinct types of receptors: the ionotropic glutamate
receptors and the metabotropic glutamate receptors (Figure 1.1). Activation of the
ionotropic glutamate receptors such as the N-methyl-D-aspartate (NMDA) and Alphaamino-3-hydroxy-5-methyl-4-isoxazole-propionic

acid

(AMPA)/Kainate

receptors

mediates a fast and short lasting cellular response by opening cation channels. In order to
produce a slow and long lasting cellular response, glutamate activates the metabotropic
glutamate receptors (Conn and Pin, 1997; Nakanishi, 1992). There are eight metabotropic
glutamate receptors divided into three subgroups based on the signaling pathways they
activate, sequence homology and pharmacological characteristics. The Group I
metabotropic glutamate receptors (mGluR1 and mGluR5) are excitatory and are coupled
to Gαq. The Group II (mGluR2 and mGluR3) and Group III metabotropic glutamate
receptors (mGluRs4, mGluR6, mGluR7 and mGluR8) are similar in that they are
involved in presynaptic inhibition by coupling to Gαi. However, these receptors differ in
their agonist selectivity (Nakanishi, 1994; Conn and Pin, 1997). The focus of this thesis
will be on the Group I mGluRs.

1.2.1 Structure and functional domains
The general structure of Group I mGluRs consists of a long amino (N)-terminal
extracellular domain tail, seven transmembrane domains separated by short intracellular
and extracellular loops, and an intracellular carboxyl (C)-terminal domain that varies in
length between splice variants (Pinn and Duvoisin, 1995). Interestingly, mGluRs share
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very little sequence homology with prototypic GPCRs and thus have unique structural
differences. Unlike prototypic GPCRs where ligand binding involves pocket formation
by the seven transmembrane domains, glutamate binding to mGluRs involves the Nterminal domain (Chun et al., 2012). Group I mGluRs have a long N-terminal domain
consisting of 600 amino acids. Structural studies have indicated that the glutamate
binding site is located in this region and forms a ‘clam shell’ upon glutamate binding.
This type of ligand binding is known as the venus fly trap model (Kunishima et al.,
2000). Besides functioning as ligand binding domains, the N-termini of Group I mGluRs
form disulphide bridges which allows for the formation of dimers (Beqollari and
Kammermeier, 2010).
In contrast to prototypic GPCRs, where G protein coupling selectivity is mediated
by the third intracellular loop, mGluRs have a highly conserved third intracellular loop,
which does not determine G protein coupling selectivity. Instead, G protein coupling
selectivity of mGluRs is mediated by the second intracellular loop where differences exist
between different subtypes of mGluRs (Gomeza et al., 1996). In addition, the second
intracellular loop is an important site for interaction with regulatory proteins such as G
protein-coupled receptor kinase 2 (GRK2), proline-rich tyrosine kinase 2 (pyk2) and
calcineurin inhibitor (CAIN) (Dhami et al., 2002, Nicodemo et al., 2010; Ferreira et al.,
2009).
Diversity in the Group I mGluRs occurs as a result of alternative splicing
mechanisms within the C-terminal tail. mGluR1 consists of four splice variants
(mGluR1a, b, c and d) and mGluR5 consist of two splice variants (a and b). mGluR1a has
a long C-terminal tail consisting of 313 amino acids. In contrast, the mGluR1b/c/d splice
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variants have short C-terminus tails (20 residues for mGluR1b, 11 for mGluR1c and 26
for mGluR1d) (Conn and Pin, 1997). The differences in length contribute to the
differences in affinity for agonists: mGluR1a has a higher affinity for agonist than the
shorter mGluR1 splice variants (Flor et al., 1996). Moreover, splice variants display
differential distribution in the central nervous system (Ferraguti et al., 1998). Both
mGluR5a and mGluR5b splice variants have long C-terminal tails. The C-terminal tail of
mGluR5a is 344 amino acids in length and mGluR5b contains an additional 32 amino
acids (Joly et al, 1995) (Figure 1.1). Because of the large C-terminal tail of Group I
mGluRs this region is important for interacting with many regulatory proteins. The Cterminus of Group I mGluRs encodes for binding motifs for PP1γ1, SIAH-1a, Homer and
PDZ domain containing proteins (Enz, 2012). In addition, the C-terminal tail is important
for G protein coupling (Francesconi and Duvoisin, 1998).
Pharmacologically, Group I mGluRs are selectively activated by the Group I
mGluR agonist (S)-3,5-Dihydroxyphenylglycine (DHPG). The most potent agonist of the
Group I mGluRs is quisqualic acid, although it can also activate the AMPA receptors.
Currently there are no agonists that differentiate between mGluR1 and mGluR5, however
the synthetic agonist CHPG is more selective for mGluR5 than mGluR1 (Doherty et al.,
1997). There are also antagonists which are selective for the two receptor subtypes: 2Methyl-6-(phenylethynyl) pyridine (MPEP) is non-competitive inhibitor of mGluR5 and
LY367385 competitively inhibits mGluR1 (Gasparini et al., 1999; Clark et al., 1997).

1.2.2 Distribution
Group I mGluRs display differential distribution patterns throughout the central
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Figure 1.1

Schematic illustration

of membrane topology of rat mGluR5. The

mGluR5b splice variant contains an insert of 32 additional amino acids after L875.
Several binding domains for interacting proteins are labeled as well as potential PKC and
CaMKII phosphorylation sites. Residues involved in Gαq/11 coupling are highlighted in
yellow. (Taken from Mao et al., 2008)
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nervous system which may contribute to the functional differences observed between
mGluR1 and mGluR5 (Ferraguti and Shigemoto 2006). mGluR1 is highly expressed in
the Purkinje cells of the cerebellum, CA3 pyramidal cells of the hippocampus, olfactory
bulb, thalamus and substantia nigra. In contrast, mGluR5 is expressed in only 10% of the
Golgi cells of the cerebellum, but is found to have a higher expression in the cortex,
striatum, olfactory bulb and the CA1 and CA3 pyramidal cells of the hippocampus
(Ferraguti and Shigemoto, 2006). The expression of Group I mGluRs in the hippocampus
plays a role in long-term potentiation (LTP) and spatial learning (Neyman and ManahanVaughan, 2008; Balschun et al., 1999). Meanwhile, the predominant expression of
mGluR1 in the cerebellum is reported to play a role in long- term depression (LTD)
induction and motor learning (Aiba et al., 1994).
More complexity occurs as a result of differential distribution of mGluR1 splice
variants. A prime example is the predominant expression of mGluR1a in the cerebral
Purjinke cells and mGluR1b in the hippocampal pyramidal cells (Ferraguti et al., 1998).
In contrast, only slight differences occur in the expression of the two mGluR5 isoforms
although it has been shown that mGluR5a predominates in the young rat brain while
mGluR5b is predominately found in the adult rat brain (Joly et al., 1995; Romano et al.,
1996). In addition, mGluR5 expression is also observed in other cell-types of the brain
such as astrocytes and microglia (Schools and Kimelberg, 1999; Biber et al., 1999).
Besides the central nervous system, Group I mGluRs have been shown to be present in
the rat spinal cord, heart cells, hepatocytes, osteoblasts and human melanocytes (Dhami
and Ferguson, 2006).
At the subcellular level, the Group I mGluRs are predominately located on the
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perisynaptic region of the post synaptic membrane where they can modulate ion channels
to regulate neuronal excitability (Lujan et al., 1996). Interestingly, mGluR5 is also
expressed on the intracellular membranes of the endoplasmic reticulum and nucleus,
where it plays a role in regulating gene expression and activates signaling cascades
distinict from cell surface counterparts (Kumar et al., 2012; Jong et al., 2009).

1.2.3 Group I metabotropic glutamate receptor signaling
As previously mentioned, Group I mGluRs are coupled to Gαq/11. Upon agonist
stimulation, Group I mGluRs change conformation allowing the exchange of GDP to
GTP on the Gαq/11 protein. The activation of the Gαq/11 protein results in the activation of
phospholipaseCβ (PLCβ) which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2)
on the plasma membrane producing the second messengers diacylglycerol (DAG) and
inositol 1,4,5-trisphosphate (IP3). IP3 interacts with the IP3 receptor on the endoplasmic
reticulum resulting in the release of Ca2+ from intracellular stores. The increase in both
Ca2+ and DAG activates protein kinase C (PKC) which in turn can activate other
downstream signaling pathways (Pinn and Duvoisin, 1997). Although Group I mGluRs
are predominately coupled to Gαq/11, they have also been shown to couple to other G
proteins, such as Gαs and Gαi/o in a variety of cell lines (Franscesconi and Duvoisin 1998;
Ribeiro et al., 2010a). Activation of Gαs stimulates adenylyl cyclase to produce cAMP,
an important second messenger. Conversely, activation of Gαi/o negatively regulates
adenylyl cyclase and inhibits cAMP formation.
Activation of PKC can lead to the activation of phospholipase D, phospholipase
A2, mitogen activated protein kinase (MAPK) as well as the modulation of a variety of

7

ion-channels (Dhami and Ferguson, 2006). mGluR1-mediated PKC activation has been
shown to phosphorylate the NMDA receptor leading to increased NMDA receptor
channel conductance, and therefore enhanced synaptic excitability (Skeberdis et al.,
2001). In addition, PKC is believed to be involved in the two distinct types of Ca2+
responses. mGluR5-mediated Ca2+ signaling is unique from that of mGluR1 as mGluR5
activation results in high frequency Ca2+ oscillations, whereas activation of mGluR1
shows low frequency Ca2+ oscillations (Kawabata et al., 1998, Dale et al. 2001). The
proposed mechanism involves the repetitive translocation of PKC between the cytoplasm
and the plasma membrane in response to repetitive G protein coupling. The oscillation
frequency is controlled by a single amino acid residue in the G protein coupling domain
that differs between mGluR1 and mGluR5 (Dale et al., 2001). The activation of MAP
kinases through Group I mGluRs involves a variety of mechanisms and will be discussed
in detail below.

1.2.4 Activation of Mitogen Activated Kinases
Protein phosphorylation is a common post-transcriptional modification that
functions to either activate or deactivate an enzyme and is widely seen in signaling
cascades. The mitogen-activated protein (MAP) kinases are a family of serine/threonine
kinases involved in the transduction of externally derived signals. This family includes
the extracellular signal-regulated kinases ERK1 and ERK2, also known as p42/p44 MAP
kinases. ERK1/2 can be activated by a variety of cell surface receptors and therefore acts
as convergence point for integration of signals (Roskoski, 2012). Initially, ERK1/2
activation was studied in mitogenic signaling downstream of receptor tyrosine kinases. In
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this signaling cascade, activation of Ras leads to the activation of the protein kinase c-raf
which in turn activates the mitogen-activated protein kinase kinases (MEK1 and MEK2).
MEK1/2 are dual function kinases that in turn carry out the phosphorylation and
activation of ERK1/2 (Roskoski, 2012). Activated ERK1/2 have a variety of cellular and
nuclear substrates that they act upon to regulate cell adhesion, migration, differentiation,
proliferation, and transcription (Roskoski, 2012). Interestingly, this signaling pathway is
upregulated in a variety of cancers (Pearson et al., 2001).
ERK1/2 phosphorylation can also be induced through activation of GPCRs
including the Group I mGluRs through a number of mechanisms depending on cell type
(Ferraguti et al., 1999; Choe and Wang, 2001; Karim et al., 2001). Group I mGluRmediated ERK1/2 phosphorylation is observed in Chinese hamster ovary cell lines
(Thandi et al., 2002). In this cell line mGluR5-mediated ERK1/2 activation is Ca2+independent, although other studies using striatal neurons have reported that Ca2+ release
from intracellular stores via the activation of PLCβ contributes partially to ERK1/2
phosphorylation (Mao et al., 2005a). In striatal neurons mGluR5-mediated ERK1/2
activation is largely due to interaction with Homer proteins (Mao et al., 2005a).
Homer1b/c proteins directly interact with mGluR5 to couple the receptor to ERK1/2
phosphorylation, since the disruption of the mGluR5-Homer1b/c interaction by TAT
interference peptides inhibits ERK1/2 phosphorylation (Mao et al., 2005a). In rat striatal
neurons mGluR5 mediated ERK1/2 phosphorylation appears to involve protein
phosphatase 2A (PP2A) (Mao et al., 2005b). mGluR5 associates with PP2A and
activation of mGluR5 inhibits this interaction and decreases PP2A activity.
Consequently, the decrease in PP2A activity contributes to mGluR5-mediated ERK1/2
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phosphorylation (Mao et al., 2005b). Our lab has found that pyk2 facilitates mGluR1dependent ERK1/2 phosphorylation in mouse cortical neurons (Nicodemo et al., 2010)
In cortical astrocytes, mGluR5-mediated ERK2 activation is independent of
PLCβ1 however and requires the transactivation of the EGF receptor, a receptor tyrosine
kinase (Peavy et al., 2001). Interestingly, it appears that transactivation of receptor
tyrosine kinases is a common mechanism by which GPCRs activate the ERK1/2 pathway
as this mechanism is described for a variety of GPCRs such as the thrombin, angiotensin
II, bradykinin, endothelin, and purinergic receptors (Daub et al., 1997; Soltoff, 1998;
Adomeit et al., 1999; Della Rocca et al., 1999; Seo et al., 2000).
Another important pathway for ERK1/2 activation involves β-arrestins. βarrestins are well known for their role in the desensitization and internalization of GPCRs
(Ferguson 2001). However, they have also been reported to function as signal transducers
by forming signaling complexes (Ferguson, 2001; Luttrell and Lefkowitz, 2002). Emery
et al., (2010) found that sustained activation of ERK1/2 phosphorylation through
mGluR1 is dependent on β-arrestin1. This signaling pathway is distinct from the G
protein-mediated transient ERK1/2 phosphorylation and is shown to be neuroprotective
(Emery et al., 2010). β-Arrestin-mediated ERK1/2 signaling has also been reported for
other GPCRs including the angiotensin II type 1a receptor (Luttrell et al., 2001), D3
dopamine receptor (Beom et al., 2004), β2-adrenergic receptor (Luttrell et al., 1999;
Shenoy et al., 2006) and the µ opioid receptor (Macey et al., 2006).

1.2.5 Regulation by interacting proteins
Protein interactions with GPCRs represent a large source for novel drug targets.
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Group I mGluRs interact with a number of regulatory proteins that are important for
receptor trafficking, protein scaffolding and coupling to distinct signaling cascades (Enz,
2012). Work done in our laboratory has characterized the interaction between GRK2,
CAIN and Pyk2 with the second intracellular loop domain of Group I mGluRs (Dhami et
al., 2002, Ferreira et al., 2009, Nicodemo et al., 2010). GRK2 interacts with the second
intracellular loop, as well as the C-terminal tail of Group I mGluRs. This interaction
functions to attenuate Group I mGluR-mediated signaling and contributes to
phosphorylation-independent internalization of Group I mGluRs in striatal neurons
(Dhami et al, 2002, 2004, 2005; Ribeiro et al., 2009). Similarly, CAIN interacts with the
second intracellular loop and C-terminus tail and attenuates mGluR1-mediated signaling
(Ferreira et al., 2009). As previously mentioned, the second intracellular loop is important
for G protein coupling. It appears that the interaction between second intracellular loop
interacting proteins disrupts coupling to Gαq/11 thus attenuating the signaling response.
The long C-terminus tail of Group I mGluRs also harbours binding sites for many
interacting proteins. The most studied are the Homer proteins, which are a family of
multifaceted scaffolding proteins (Thomas 2002). Homer proteins bind to the proline rich
region of the C-termius tail of Group I mGluRs and are proposed to physically link both
mGluR1 and mGluR5 to the IP3 receptor thereby modulating Ca2+ release (Tu et al.,
1998). In addition, the interaction between mGluR5 and Homer3 has been shown to
prevent constitutive activity of the receptor (Ango et al., 2001). Other proteins interact
with the C-terminal tail to modulate receptor cell surface expression and trafficking.
Calmodulin (CaM) interacts with mGluR5 and is reported to play a role mGluR5
trafficking (Lee et al., 2008). Specifically, CaM overexpression increases cell surface
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expression of mGluR5 while the knockdown of CaM decreases cell surface expression.
CaM also competes with PKC for binding to the C-tail of mGluR5 and thus regulates
PKC-mediated trafficking of mGluR5 (Lee et al., 2008).

1.2.6 Physiological roles of Group I mGluRs
Group I mGluRs have been extensively studied in experimental animals leading to
the conclusion that they are involved in many aspects of brain function. In the brain,
activation of Group I mGluRs plays a complex role that can be both neuroprotective and
neurotoxic (Nicoletti et al., 1999; Caraci et al., 2012). Group I mGluRs have been
implicated in the two forms of synaptic plasticity: LTP and LTD, indicating that are
involved in the underlying mechanisms for learning and memory (Riedel and Reyman
1996, Ayala et al., 2009; Neyman and Vaughan, 2008). LTP involves a mechanism in
which persistent synaptic activity leads to a pronounced increase in synaptic strength. In
contrast, in LTD an absence of synaptic activity leads to a pronounced decrease in
synaptic strength (Anwyl, 1999).
LTP is thought to occur in two phases: early phase LTP and late phase LTP. Early
phase LTP is mediated by the activation of NMDA receptors which results in increased
intracellular Ca2+ and subsequent activation of CaMKII (Lisman et al., 2002). CaMKII is
responsible for strengthening of the synapse by increasing the number of AMPA
receptors on the synaptic membrane (Lynch, 2004). Importantly, the insertion of AMPA
receptors at the synapse occurs in a protein synthesis independent manner. This is
achieved by the trafficking of existing nonsynaptic AMPA receptors to the synaptic
membrane (Malinow, 2003). In contrast, late phase LTP depends on protein synthesis and
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activation of mGluRs (Neyman and Vaughan, 2008). There is now a considerable amount
of evidence that shows that certain forms of LTP are dependent on Group I mGluRs (Lu
et al., 1997; Jia et a., 1998; Neyman and Vaughan, 2008). The perisynaptic localization of
Group I mGluRs at excitatory synapses puts these receptors at an ideal location for
regulating synaptic strength. One mechanism involves the mGluR5-mediated
enhancement of NMDA receptor conductance (Attuci et al., 2001). In line with this,
studies on mGluR5 knockout mice have revealed that NMDA-dependent LTP in the CA1
region of the hippocampus is reduced and that these mice exhibit impaired learning (Lu et
al., 1997; Jia et a., 1998).
Besides their role in normal brain functions, Group I mGluRs have also been
implicated in a variety of neurological disorders. Perhaps the most studied is the role of
mGluR5 in the pathogenesis of Fragile-X syndrome. Fragile-X syndrome is the leading
genetic cause of autism in which the gene encoding for Fragile-X mental retardation
protein (FMRP) is silenced (Pieretti et al., 1991). FMRP is an RNA binding protein that
selectively binds to 4% of mammalian mRNAs and represses their translation (Ashley et
al., 1993). mGluR5 plays an important role in Fragile-X since both inhibition mGluR5
signaling and knockdown of mGluR5 improves Fragile-X phenotypes in FMRP knockout
mice (Bear et al., 2004; Dölen and Bear, 2008). Additionally, mGluR-dependent LTD is
exaggerated in the hippocampus of FMRP knockout mice which could impair synaptic
plasticity and lead to memory deficits (Luscher and Huber, 2010)
Because of their involvement in LTP and LTD, it is no surprise that Group I
mGluRs play a role in neurodegenerative diseases that affect learning and memory such
as Huntington’s and Alzheimer’s diseases (Ribeiro et al., 2010). Huntington’s disease is
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an autosomal-dominant neurodegenerative disorder that affects muscle coordination,
cognition and mental behavior (Ribeiro et al., 2011). Our lab has demonstrated that
Group I mGluR signaling is altered in a knock-in mouse model of Huntington’s disease
(Ribeiro et al., 2010b; Ribeiro et al., 2014). Specifically, Group I mGluR mediated IP3
formation is decreased and Ca2+ release is increased compared to wild type control
(Ribeiro et al., 2010b). Moreover, the mGluR5 antagonist MPEP is reported to prolong
survival in a mouse model of Huntington’s disease (Schiefer et al., 2004).
Several studies have implicated Group I mGluRs in Alzheimer’s disease.
Alzheimer’s disease is a progressive neurodegenerative disease characterized by
cognitive impairment, memory loss and behavioral changes (Tsai et al, 2005).
Alzheimer’s disease has a distinct pathology consisting of Amyloid β (Aβ) plaques and
tangles of hyperphosphorylated tau (Holzman et al., 2011; Nelson et al., 2009; Hardy et
al., 2002). Aβ can exert its effects by blocking LTP thereby reducing synaptic plasticity.
Wang et al., (2004) found that the Aβ-mediated inhibition of LTP can be prevented by
the mGluR5 antagonist MPEP. Recently it has been shown that genetic deletion of
mGluR5 reverses spatial memory deficits in the APPswe/PS1E9 mouse model of
Alzheimer’s disease (Hamilton et al., 2014). Furthermore, genetic deletion of mGluR5 in
this mouse model results in reduced Aβ oligomer formation compared to the
APPswe/PS1E9 mice expressing mGluR5 (Hamilton et al., 2014). Taken together, these
observations suggest that Group I mGluRs are important regulators of normal brain
function and dysregulation of these receptors can be a factor in disease progression.
1.3 Amyloid β
Aβ is formed from the sequential cleavage of the amyloid precursor protein (APP)
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by β- and γ-secretases (Vardy et al., 2005). APP is a transmembrane protein that can be
processed by two alternate pathways. In the non-amyloidogenic pathway, α-secretase
cleaves APP within the Aβ region thus preventing the formation of the Aβ peptide. In
the amyloidogenic pathway, APP is initially cleaved by β-secretase resulting in the
release of the N-terminal fragment, sAPPβ. The remaining C-terminal of APP is
membrane bound and is cleaved by γ-secretase to produce Aβ peptide and amyloid
intracellular domain (Figure 1.2) (Vardy et al., 2005; Chow et al., 2009). Once cleaved,
Aβ peptide can form a variety of structures including monomers, oligomers and fibrils
(Zhang et al., 2011). Cleavage by γ-secretase results in a number of Aβ peptide isoforms
that vary in length between 39 and 43 amino acids. Aβ40 and Aβ42 are the most common
Aβ species. However, Aβ42 peptides assemble more readily into oligomeric forms and
are a major component of amyloid plaques (Selkoe 2006; Kellett and Hooper, 2009).
Furthermore, Aβ42 oligomers correlate better with neurotoxicity than any other form of
Aβ (Lacor et al., 2007; Butterfield 2002)
Aβ oligomers can exert their toxic affects by targeting synapses and contributing
to synaptic dysfunction and synaptic loss (Lacor et al., 2007, Shankar et al., 2007). In
addition, several studies have indicated that Aβ-mediated toxicity involves inhibition of
LTP (Walsh et al., 2002). Aβ can suppress both early phase and late phase LTP which
can explain the learning and memory deficits associated with Alzheimer’s disease (Chen
et al., 2000, Zhang et al., 2009; Li et al., 2009). The exact molecular mechanisms
underlying Aβ-mediated toxicity are largely unknown. It is proposed that Aβ oligomers
may exert their neurotoxic effects by interacting with several cell surface receptors
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Figure 1.2. Schematic illustration of the β- and γ-site cleavage events required for
Aβ formation. The amyloid precursor protein (APP) is a 100 kDa transmembrane
protein that is initially cleaved at the beta site by the enzyme BACE. This releases the
extracellular APP fragment β-APP leaving the C-terminal APP C99 fragment in the
membrane. Cleavage at the beta site can be followed by a second cleavage within the
membrane domain of APP by the γ-secretase complex to produce beta amyloid (Aβ).
This “gamma-cleavage” determines the relative amount of the more toxic 42 amino acid
form of Aβ produced.
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(Dinamarca et al., 2012). Several studies have shown that Aβ can affect the function of
NMDA receptors. Aβ binds to the NMDA receptor, contributes to NMDA receptor
endocytosis and depresses NMDA receptor-evoked currents. (Snyder et al., 2005;
Shankar et al., 2007). Aβ can also bind to the α7-nicotinic acetylcholine receptor (α7nAChR) with high affinity (Wang et al., 2000). The same group discovered that the α7nAChR can mediate Aβ peptide-induced tau protein phosphorylation (Wang et al., 2003).
Aβ42 oligomers have been shown to bind with high affinity to the cellular prion protein
(PrPC) and reduce LTP in hippocampal slices of wildtype mice but not PrPC-null mice,
suggesting that PrPC mediates Aβ42 oligomer toxicity (Lauren et al., 2009). PrPC is a
glycosylphosphatidylinositol-anchored membrane protein that is highly expressed within
the central nervous system (Linden et al., 2007). Its pathogenic form, the abnormally
folded scrapie prion protein PrPSc, is well known for its role in neurodegenerative
disorders known as transmissible spongiform encephalopathies (Linden et al., 2007).
Normal physiological roles of PrPC include neuroprotection to oxidative stress, cell
adhesion and neurite growth (Linden et al., 2007).
Recent studies have shown that Aβ42 oligomers may produce their toxic effects
through mGluR5 (Renner et al., 2010). Aβ42 oligomers induce clustering of mGluR5
resulting in limited lateral diffusion of the receptors and elevated Ca2+ levels that cause
synaptic deterioration (Renner et al., 2010). Additionally, mGluR5 has been shown to be
a co-receptor for the Aβ oligomer-PrPC complex (Um et al., 2013). Aβ oligomers can
increase intracellular Ca2+ in neurons in a manner that is dependent on both mGluR5 and
PrPC.
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1.4 Ca2+/ Calmodulin-dependent protein kinase II
Regulation of Ca2+ signaling is a vital component in the maintenance of cellular
homeostasis. In the brain, Ca2+ signaling regulates many aspects of neuronal excitability
by interacting with a variety of Ca2+ sensitive proteins (Zundorf and Reiser, 2011).
Ca2+/CaM-dependent protein kinase II (CaMKII) is a serine/threonine kinase that is
sensitive to Ca2+ signaling since it is activated by Ca2+/CaM binding when intracellular
Ca2+ is increased. CaMKII comprises a family of 28 similar isoforms derived from four
genes (α, β, γ, and δ). The expression of the γ and δ isorforms is ubiquitous whereas the
α and β isoforms are restricted to neuronal tissue (Lisman et al., 2002). CaMKIIα and
CaMKIIβ are highly abundant in the brain where they are estimated to make up 1-2% of
the total protein (Erondu and Kennedy, 1985). Specifically, CaMKIIα/β is expressed in
the cortex, striatum, cerebellum, hypothalamus, olfactory bulb and its highest expression
is observed in the hippocampus (Erondu and Kennedy, 1985). At the subcellular level,
CaMKIIα/β can be found in the cytoplasm as well as a protein dense region of the postsynaptic membrane known as the post synaptic density (PSD) (Hanson and Schulman,
1992). This thesis will focus on the CaMKIIα isoform.

1.4.1 Structure and activation of CaMKII
Each isoform of CaMKII consists of an autoinhibitory domain, a catalytic
domain, a self-association domain and a variable segment. The self-association domain at
the C-terminus allows for the assembly of a holoenzyme comprised of 12 subunits. The
resulting structure resembles that of a hub and spoke in which the catalytic domains are
arranged in a ring around a central scaffold formed by the self-association domains
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(Lisman et al., 2002; Chao et al., 2011). Under basal conditions, the autoinhibitory
domain binds to the catalytic domain, preventing any kinase activity. An increase in
intracellular Ca2+ favours Ca2+/CaM to bind to the autoinhibitory domain relieving the
inhibition to the catalytic domain. This allows for the exposure of the Thr 286 site on the
autoinhibitory domain (Thr 287 on CaMKIIβ), which can be phosphorylated by adjacent
subunits of CaMKII in a process known as autophosphorylation. Once this site is
phosphorylated the autoinhibitory domain can no longer inhibit the catalytic domain and
the catalytic domain can remain active even after Ca2+/CaM levels fall. This contributes
to the persistent or autonomous activity of the kinase (Hanson and Schulman, 1992). Two
molecules of Ca2+/CaM are required to initiate the activation of the CaMKII holoenzyme.
One binds to one subunit and activates it while the other Ca2+/CaM molecule binds to an
adjacent subunit in order to expose the Thr 286/287 site which gets phosphorylated by the
activated subunit. In contrast, propagation of activating all 12 subunits requires binding
of only one Ca2+/CaM molecule to a subunit adjacent to the one that is already
phosphorylated (Figure 1.3) (Lisman et al., 2002).

1.4.2 Role of CaMKII
CaMKII can phosphorylate a broad range of substrates and regulate a variety of
cellular functions. In the heart, CaMKIIδ has been shown to be in involved in
cardiomyocyte hypertrophy by regulating the expression of hypertrophic markers (Zhang
and Brown, 2004). In the brain, CaMKII has been shown to be an important player in
synaptic plasticity. The Threonine residue 286 on CaMKIIα in particular, has been shown
to contribute to the induction of LTP (Lisman et al., 2002; Lee et al., 2009). It was found
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Figure 1.3 Representative diagram of CaMKII structure and activation. Each
CaMKII subunit is composed of a self-association domain, a catalytic domain and an
autoinhibitory domain. Twelve subunits of CaMKII join together at the self-association
domain to form a holoenzyme. Under basal conditions, the autoinhibitory domain binds
to the catalytic domain to inhibit its activity. Upon Ca2+/CaM binding the catalytic
domain becomes active and can phosphorylate an adjacent CaMKII subunit.
Phosphorylation keeps the autoinhibitory domain from inhibiting the catalytic domain
even after Ca2+/ CaM fall resulting in autonomous activity of the enzyme. (Taken from
Lisman et al., 2002)
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that prevention of CaMKIIα activation by mutation of this residue results in impaired
LTP induction and mice exhibiting this mutation show profound memory impairment
(Giese et al., 1998; Lucchesi et al., 2011). Furthermore, mice exhibiting enhanced
learning have increased activation of CaMKII (Lee and Silvia, 2009)

1.4.3 Regulation of ionotropic glutamate receptors.
CaMKII plays an important role in LTP by interacting with the ionotropic
glutamate receptors. Once CaMKII is activated by increased intracellular Ca2+, it can
translocate from the cytoplasm to the PSD (Shen and Meyer, 1999). Here, CaMKII can
bind to a variety of different proteins and receptors. The binding to the NMDA receptor
has been key to elucidating the role of CaMKII in LTP induction. It is well established
that stimulation of NMDA receptors in cultured neurons produces an increase in Ca2+
influx which activates CaMKII. Activated CaMKIIa can then translocate to the PSD
where it binds to the NR2B subunit of the NMDA receptor (Strack et al., 1997; Leonard
et al., 1999). The formation of the NMDA-CaMKII complex has been shown to play an
important role in LTP since transgenic mice overexpressing a mutant form of NR2B
which interferes with CaMKII binding have a 50% reduction in LTP and show learning
impairments (Barria and Malinow, 2005; Zhou et al., 2007). Importantly, the binding of
CaMKII to the NMDA receptor keeps the kinase in an active state (Bayer et al., 2001).
LTP induction and maintenance is also dependent on AMPA receptor activity.
One mechanism involves the phosphorylation of AMPA receptors at a specific residue
within the GluR1 subunit by CaMKII (Lee et al., 2000). The translocation of CaMKII to
the PSD puts the kinase at an ideal location to phosphorylate the Ser 831 residue on the
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GluR1 subunit of AMPA receptors leading to an increase in conductance of these
channels and enhanced LTP (Barria et al., 1997; Poncer et al., 2002).

Another

mechanism involves the increase in AMPA receptors in the synapse. AMPA receptor
trafficking to the synapse is positively regulated by the stargazin-PSD95 complex
(Schnell et al., 2002; Bats et al., 2007). It is hypothesized that CaMKII potentiates this by
phosphorylating stargazin which allows stargazin to bind to PSD95 thereby increasing the
number of AMPA receptors at the cell surface (Lisman et al., 2012). These mechanisms
work together to enhance LTP.

1.4.4 Regulation of G protein-coupled receptors
Emerging studies reveal that CAMKIIα can also regulate several GPCRs.
CaMKIIα has been shown to regulate behavioral responses to cocaine by regulating the
Dopamine 3 (D3) receptor, a GPCR coupled to Gαi (Liu et al., 2008). CaMKIIα binds to
the long third intracellular loop of the D3 receptor and activation of CaMKIIα by
Ca2+/CaM, as well as Thr 286 autophosphorylation enhances the interaction to the D3
receptor. CaMKIIα phosphorylates the D3 receptor and contributes to receptor
desensitization, thereby relieving the inhibition of cAMP accumulation induced by D3
receptor agonists (Liu et al., 2008). CaMKIIα-dependent desensitization has also been
reported for the D1/D2 heterodimer (So et al., 2008) and the Histamine H1 receptor
(Hishinuma and Ogura, 2000).
Another Gαi coupled GPCR, the M4 muscharinic acetylcholine receptor has been
shown to be regulated by CaMKIIα (Guo et al., 2010). CaMKIIα binds to the second
intracellular loop of the M4 receptor and potentiates its signaling. Interestingly, this
interaction is enhanced by CaMKIIIα activation and autophosphorylation similar to that
which occurs at the D3 receptor. Experiments using interference peptides designed to
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block this interaction block the M4 receptor-mediated decrease in cAMP accumulation
(Guo et al., 2010). Consequently, because motor activity in the brain is coordinated by
M4 receptors, the CaMKIIα regulation of M4 receptor contributes to the integration of
signals required for motor control (Guo et al., 2010).
CaMKIIα is well studied in context of the ionotropic glutamate receptors.
However, very little is known about the effects of CaMKIIα on metabotropic glutamate
receptors. Of all eight mGluRs, CaMKIIα has only been reported to regulate mGluR1
(Mundell et al., 2002; Jin et al., 2013a). CaMKIIα appears to play a role in mGluR1
internalization: inhibition of CaMKIIα blocks the glutamate-stimulated association of
GRK2 with mGluR1a suggesting CaMKIIα plays a role in inhibiting mGluR1
internalization (Mundell et al., 2002). Recently, CaMKIIα has been shown to play a
direct role in the regulation of mGluR1 by physically interacting with the C-terminus tail
of mGluR1 (Jin et al., 2013a). Similar to that of the D3 dopamine and M4 muscarinic
receptor, activation of CaMKIIα by Ca2+/CaM binding as well as autophosphorylation
potentiates CaMKIIα binding to mGluR1. In rat striatal neurons, stimulation with DHPG
increases the amount of CaMKIIα co-immunoprecipitated with mGluR1a showing that
this occurs in physiologically relevant tissue. Functionally, CaMKIIα phosphorylates
mGluR1 at Thr 871 on the C-terminus tail and desensitizes mGluR1 mediated IP3
production in rat striatal neurons (Jin et al., 2013a). These studies suggest that CaMKIIα
can be an important regulator of GPCR activity including mGluR1.

1.5 Preliminary data and rationale
In collaboration with Dr. Stephane Angers, we have identified CaMKIIα as a
novel second intracellular loop (IL2) interacting protein of Group I mGluRs. A
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membrane permeant Tat-IL2-FLAG peptide was used to screen for novel IL2 interacting
proteins. Mouse cortical neurons were treated with the Tat-IL2-FLAG peptide and the
Tat-IL2-FLAG peptide was subsequently immunoprecipitated with FLAG agarose beads.
Immunoprecipitates were trypsinized and analyzed by Maldi-TOF Mass Spectroscopy.
mGluR1-IL2 interacting proteins identified in the screen included CaMKII isoforms α, β,
γ, δ.
Work done previously in our laboratory by Stephanie Kulhawy as part of her
M.Sc. thesis has confirmed the interaction between CaMKIIα and Group I mGluRs in
HEK

293

cells.

When

FLAG-mGluR1/5

was

immunoprecipitated,

co-

immunoprecipitation of GFP-CaMKIIα occurred with both mGluR1a and mGluR5a and
this interaction was independent of agonist stimulation with quisqualate. Additionally,
CaMKIIα was shown to interact with mGluR5 in mouse hippocampal tissue indicating
that this interaction takes place in physiologically relevant tissue. Furthermore, using a
GST-pull down assay, it was established that the second intracellular loop of mGluR1 is
sufficient for this interaction to occur.
When looking at the effects of CaMKIIα on mGluR1a signaling, it was found that
CaMKIIα overexpression had no significant effect on mGluR1a-mediated ERK1/2
phosphorylation or IP3 formation. However the role of CaMKIIα on mGluR5-mediated
signaling remains unknown. Additionally, it was found that CaMKIIα significantly
enhances agonist-mediated mGluR5 internalization but not mGluR1 internalization
suggesting that CaMKIIα has more of a pronounced effect on mGluR5. Therefore this
thesis will focus on the role of CaMKIIα on mGluR5 activity.
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1.6 Goals and Significance of Research
Interacting proteins play a vital part in GPCR regulation.

As previously

addressed, CaMKII has been shown to be an important regulator of GPCRs including
mGluR1. Furthermore, it is well established that the second intracellular loop of Group I
mGluRs is an important region for receptor regulation by interacting proteins.
Preliminary data provide evidence for a role for CaMKIIα in mGluR5 internalization,
however whether CaMKIIa plays a role in mGluR5 signaling is unknown. In this study
we hypothesize that CaMKIIα plays a role in regulating mGluR5 mediated signaling and
that Aβ oligomer interactions with mGluR5 may alter CaMKIIα/mGluR5 interactions.
We hypothesized that Aβ oligomers will produce differential effects on the regulation of
mGluR5 by CaMKII.
As previously mentioned, mGluR5 is involved in a variety of signaling pathways
that can be both neuroprotective and neurotoxic. However, factors that differentiate
between these outcomes are poorly understood. Furthermore, alterations in the regulation
of mGluR5 may lead to the progression of several neurodegenerative diseases. Therefore,
by elucidating the roles of its interacting proteins, such as CaMKIIα, on mGluR5
regulation, we may begin to better understand the mechanisms by which mGluR5 is
regulated, as well as identify novel therapeutic targets for the treatment of
neurodegenerative diseases related to mGluR5.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
Human embryonic kidney (HEK293) cells were obtained from American Type
Culture Collection (Manassas, VA, USA). Fetal Bovine Serum (FBS), minimum essential
medium (MEM), Dulbecco’s Modified Eagle Medium (DMEM), 0.25% trypsin, and
rabbit anti-GFP antibody were all purchased from Invitrogen Corporation (Burlington,
ON, Canada). Goat anti-rabbit IgG (H+L)-HRP conjugate secondary antibody, ECL
western blotting detection reagents, Dowex 1-X8 (formate form) resin 200-400 mesh and
Bradford reagent for protein assays were all obtained from Bio-Rad (Mississauga, ON,
Canada). Sheep anti-mouse IgG secondary antibody and Protein G Sepharose 4 Fast Flow
were from GE Healthcare (Mississauga, ON, Canada). Phospho-p44/42 MAP kinase
antibody and p44/42 MAP kinase antibody were purchased from Cell Signaling
Technology (Mississauga, ON, Canada). Anti-FLAG antibody and rabbit anti-FLAG M2
Agarose were purchased from Sigma (St. Louis, MO, USA). Anti–mGluR5 rabbit IgG
was purchased from Millipore (Billerica, MA, USA). Quisqualate and KN-93 were
purchased from TOCRIS (Minneapolis, MN, USA). Myo-[3H] Inositol was purchased
from Perkin Elmer (Waltham, MA, USA). Fura-2 AM and Zenon antibody labelling
reagents were purchased from Molecular Probes (Billerica, MA, USA). Aβ42 peptide was
purchased from American Peptide (Vista, CA, USA). Bisindolymaleimide I (Bis-1)
hydrochloride was purchased from Calbiochem (San Diego CA, USA). The GFPCAMKIIα cDNA was a gift from Dr. Paul De Koninck (University Laval).
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2.2 Cell culture and transfection
HEK 293 cells were maintained in MEM supplemented with 10% (v/v) fetal
bovine serum at 37°C in a humidified atmosphere containing 5% CO2. Cells were plated
on 100 mm dishes and transfected using a modified Ca2+ phosphate method (Ferguson
and Caron, 2004) with the amount of cDNA indicated in the Figure Legends. Briefly,
cDNAs were diluted in 450 µL of sterile distilled water and 50 µL of 2.5M CaCl2 was
added to the mix. Next, 500 µL of 2X HEPES-balanced salt solution (0.28 M NaCl,
0.05M HEPES, 1.5 mM Na2HPO4, pH 7.10) was slowly dripped over the cDNA/CaCl2
solution. The solution was mixed and immediately applied to cells grown to 75-85%
confluency drop by drop. Cells were washed twice with PBS 16-18 hours after
transfection and allowed to recover in MEM for 6 hours before being reseeded for
experimentation. Experiments were performed the following day except otherwise
indicated.

2.3 Co-immunoprecipitation
HEK 293 cells were transiently transfected with various cDNA constructs as
described in the Figure Legends. One day after transfection, cells were starved for 1 hour
in HBSS (1.2 mM KH2PO4, 5 mM NaHCO3, 20 mM HEPES, 11 mM Glucose, 116 mM
NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 2.5mM CaCl2, pH 7.4) and subsequently stimulated
as indicated in the Figure Legends. Cells were then lysed with ice-cold lysis buffer. (50
mM Tris, pH 8.0, 150 mM NaCl, and 0.1% Triton X-100) and insoluble material was
pelleted. FLAG-mGluR5 was immunoprecipitated from transfected HEK 293 cell lysates
using FLAG M2-Agarose prepared as a 50:50 slurry with PBS. 200 µg of protein was
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rotated with 50 µl of the slurry for 1 hour at 4°C. The beads were washed 3 times with
PBS and eluted with 100 µl of SDS loading buffer containing β-mercaptoethanol. The
eluted proteins were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
and immunoprecipitated and co-immunoprecipitated proteins were detected by Western
Blot.
2.4 GST pull down
GST-mGluR1a-IL2 and mutants were cloned into a pGEX4T1 vector and
transformed into E.coli recombinant bacteria. E. coli bacteria were grown at 37°C with
shaking until OD600 was 0.6-1.0. Cultures were then induced with 1 mM isopropyl 1-thioβ-D-galactopyranoside for 3 hours at 23°C. Cells were pelleted and lysed in lysis buffer
(500 mM NaCl, 0.5% NP-40, 50 mM Tris pH7.6, 5 mM EDTA, 5 mM EGTA)
containing protease inhibitors (2 mM AEBSF, 50 mg/ml aprotinin, 20 mg/ml leupeptin)
and sonicated (3 times for 10 seconds) at 4°C. Insoluble material was pelleted at 15000 g
for 15 minutes at 4°C. 50 µl of Glutathione-Sepharose bead slurry was incubated
overnight with 1 ml of solubilized protein to purify GST-fusion constructs. GlutathioneSepharose beads were then washed 3 times in PBS and 500 µg of HEK 293 cell lystate
overexpressing GFP-CAMKIIα was added to the GST-fusion peptide bound to matrix
and rotated for 1 hour at 4°C. Glutathione-Sepharose beads were then washed 6 times in
PBS and eluted with 3X SDS loading buffer containing β-mercaptoethanol. Samples were
subjected to SDS-PAGE and membranes were immunoblotted with GFP to determine if
GFP-CAMKIIα was pulled down with the GST-mGluR1a-IL2 peptides.
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2.5 ERK1/2 phosphorylation
Twenty-four hours after transfection, cells were reseeded into 6-well dishes. The
following day, cells were starved in DMEM overnight. On the day of experiment, cells
were starved for an additional hour in HBSS. Cells were then stimulated at 37°C with
either 50 µM Quisqualate or 100 nM Aβ42 oligomers as indicated in the Figure Legends.
For experiments using the PKC inhibitor, 1 µM Bis-1 or DMSO (vehicle) was added 30
minutes prior to stimulating cells. Cells were subsequently lysed in lysis buffer (25 mM
HEPES, 300 mM NaCl, 1.5 mM MgCl2, 200 µM EDTA, 1% Triton-X) containing
protease and phosphatase inhibitors ( 1 mM AEBSF, 25 mg/ml aprotinin, 10 mg/ml
leupeptin, 10 mM NaF, 100 µM Na3VO4) rocking at 4°C. Lysates were collected and
centrifuged at 15000 RPM for 15 minutes at 4°C. Protein concentration was determined
using a Bradford protein assay. The lysates were mixed with SDS loading buffer
containing β-mercaptoethanol prior to gel loading. ERK1/2 phosphorylation was
determined by immunoblotting for phospho-ERK1/2 and Total-ERK1/2 and the ratio was
normalized to basal levels.

2.6 Inositol phosphate formation
Forty-eight hours after transfection, inositol lipids were radiolabelled by
incubating HEK293 cells overnight with 1 µCi/ml [3H]myo-inositol in DMEM.
Unincorporated [3H]myo-inositol was removed by washing the cells 3X with warm
HBSS. HEK 293 cells were then incubated for 1 hour in warm HBSS at 37°C and then
for an additional 10 minutes in HBSS containing 10 mM LiCl. Subsequently, cells were
treated with increasing concentrations of quisqualate (0-30 µM) for 30 minutes at 37°C.
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The reaction was terminated by placing the cells on ice and adding 500 µl of 0.8 M
perchloric acid and then neutralized with 400 µl of 0.72 M KOH and 0.6 M KHCO3.
Total [3H]myo-inositol incorporated into the cells was determined by counting the
radioactivity present in 50 µl of cell lysates. Total inositol phosphate was purified from
the cell lysates by anion exchange chromatography using Dowex 1-X8 (formate form)
200-400 mesh anion exchange resin. [3H]myo-inositol phosphate formation was
determined by liquid scintillation using a Beckman LS 6500 scintillation counter.

2.7 Calcium Imaging
HEK 293 cells were washed 2X in KRH buffer (125 mM NaCl, 5 mM KCl, 2
mM CaCl2, 2.6 mM MgSO4, 5 mM HEPES, pH 7.2). mGluR5 was labelled with rabbit
anti-FLAG-conjugated Zenon Alexa Fluor 555 antibody for 20 minutes. Intracellular
Ca2+ was then labeled with 5 µM fura-2 acetoxymethyl ester (AM) in KRH buffer for 30
minutes and washed off prior to loading onto PTI DeltaRam microscope. Cells
expressing both FLAG-mGluR5 and GFP-CaMKII or GFP empty vector were selected to
be imaged. Fluorescence intensity was examined by illuminating the cells with 340 and
380 nm and the intensity values at each excitation were recorded. After obtaining a one
minute baseline, cells were stimulated with 30 µM Quisqualate for 5 minutes.
Concentration of Ca2+ was obtained by using the formula [Ca2+] = Kd * [R-Rmin]/
[Rmax-R] * Fmax/Fmin, where R is the Fura-2 340/380 ratio, Kd =.761 µM,
Rmin=0.196, Rmax=6.907, and Fmax/Fmin=9.558, as determined by calibration
experiments. Area under the curve was determined using GraphPad software.
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2.8 Immunofluorescence confocal microscopy
Confocal microscopy was performed using a Zeiss LSM-510 laser scanning
microscope equipped with a Zeiss 63X 1.4 numerical aperture oil immersion lens. Live
cell imaging was performed on HEK293 cells in 35mm glass-bottomed plates. mGluR5
was labelled with rabbit anti-FLAG conjugated Zenon Alexa Fluor 647 antibody and
PrPC was labeled with mouse anti-PrPC conjugated Zenon Alexa Fluor 555 IgG2B
antibody. Visualization of labelled proteins with GFP-CaMKIIα was performed by triple
excitation (488/543/647 nm), and emissions were collected using these filter sets: band
pass from 505-530 (GFP), long pass at 560 (Alexa Fluor 555) and 660 (Alexa Fluor 647).
For internalization experiments, FLAG-mGluR5 was labelled with rabbit anti-FLAGconjugated Zenon Alexa Fluor 555 antibody. Visualization of antibody-labelled receptor
with GFP-CaMKIIα was performed by dual excitation (488/543 nm) and emission band
pass from 505-530 (GFP) and long pass at 560 (Alexa Fluor 555) filter sets. Receptor was
stimulated with the addition of 30 µM Quisqualate (final concentration) for 20 minutes.

2.9 Immunoblotting
Nitrocellulose membranes were blocked for 1 hour with 10% milk in Trisbuffered Saline with Tween 20 (TBS-T) (150mM NaCl, 10 mM Tris HCl pH 7.0, and
0.05% Tween 20) and subsequently incubated overnight with primary antibody (1:1000)
in TBS-T containing 3% milk. Membranes were washed 3X in TBS-T and then incubated
with secondary horseradish peroxidase conjugated goat anti-rabbit IgG (1:5000) or sheep
anti-mouse IgG (1:5000) in TBS-T containing 3% milk for 1 hour. Membranes were then
rinsed 3X with TBS-T and incubated with enhanced chemiluminescence Western blotting
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detection reagents and visualized using a Chemidoc Imaging System.
2.10 Aβ42 oligomer formation
Aβ42 peptides stored at -80°C were allowed to equilibrate to room temperature
prior to dilution to 1 mM with 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). HFIP was
evaporated in a vacuum centrifuge in order to form Aβ42 peptide films and films were
then stored at -80°C.

Prior to use, Aβ42 peptide films were diluted in

dimethylsulphoxide (DMSO) to 1 mM and sonicated for 10 minutes in a Branson
sonicator. Aβ42 peptides were then subsequently diluted to 100 µM in ice-cold F-12 cell
culture media (phenol free red), vortexed immediately for 30 seconds, and incubated at
4°C for 24 hours in order to form Aβ42 oligomers.

2.11 Statistical Analysis
The means ± S.E.M. are shown for values obtained for the number of independent
experiments indicated in the Figure Legends. Immunoblots were quantified using Image
Lab software. GraphPad Prism software was used to analyze data for statistical
significance as well as to analyze and fit dose-response curves. Statistical significance
was determined by either an unpaired two-tailed t-test or by one-way ANOVA followed
by Tukey’s or Dunnett’s multiple comparison’s test.
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CHAPTER 3
RESULTS
3.1 Characterization of the interaction between CAMKIIα and mGluR5
CaMKIIα was previously shown to interact with mGluR1 (Jin et al., 2013a). We
also previously identified CaMKIIα as an mGluR1/5 interacting protein following
immunoprecipitation of the 2nd intracellular loop domain (IL2) of mGLuR1a/5a to
identify mGluR1a/5a interacting proteins by proteomic analysis (Angers and Ferguson,
unpublished observations). Consistent with this experiment, we found that GFPCaMKIIα could be co-immunoprecipitated with the full-length FLAG-tagged mGluR5a
in transfected HEK 293 cells in an agonist-independent manner (Fig. 3.1A).
Ca2+/CaM has been demonstrated to bind to the regulatory domain of CaMKIIα to
activate the kinase. This activation can regulate the affinity of CaMKIIα for its targets
such as the NMDA receptor (Shen and Meyer, 1999) and previous studies showed that
activation of CaMKIIα by Ca2+/CaM increases its interaction to GPCRs such as the D3
receptor, the M4 muscarinic receptor and mGluR1a (Liu et al., 2008; Guo et al., 2010; Jin
et al., 2013a). Therefore, we examined whether inhibition of CaMKIIα activity can
decrease the association between CaMKIIα and FLAG-mGluR5a as determined by coimmunoprecipitation. KN-93 is a CaMKII inhibitor which prevents activation by binding
to the Ca2+/CaM binding site on the kinase (Sumi et al., 1991). Agonist stimulation of
mGluR5a did not affect the amount of GFP-CaMKIIα co-immunoprecipitated with
FLAG-mGluR5a and KN-93 treatment did not affect the amount of GFP-CaMKIIα coimmunoprecipitated with FLAG-mGluR5a indicating that this interaction was agonist-
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Figure 3.1. CaMKIIα co-immunoprecipitates with mGluR5 independent of agonist
stimulation and CaMKIIα activity. (A) Representative immunoblot of GFP-CaMKIIα
co-immunoprecipitated with FLAG-mGluR5a in HEK 293 cells transiently transfected
with 2 µg of FLAG-mGluR5 and 0.5 µg of GFP-CaMKIIα as labelled. Cells were
stimulated with 30 µM quisqualate for the indicated time points. (B) Representative
immunoblot of GFP-CaMKIIα co-immunoprecipitated with FLAG-mGluR5a in HEK
293 cells transiently transfected with 2 µg of FLAG-mGluR5 and 0.5 µg of GFPCaMKIIα as labelled. Cells were treated with 5 µM of the CaMKIIα inhibitor KN-93 for
1 hour. (C) Effect of KN-93 treatment was quantified by densitometry and had no
significant effect on the amount of GFP-CaMKIIα co-immunoprecipitated with FLAGmGluR5. Data are representative of the mean ± S.E.M of five independent experiments.
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and CaMKIIa-activity independent (Fig. 3.1 B and C). GFP-CaMKIIα is localized in the
cytosplasm when expressed alone in HEK293 cells and when co-expressed with FLAGmGluR5 (Figure 3.2 A and B). Stimulation of mGluR5 with quisqualate does not alter the
distribution of GFP-CaMKIIα (Fig. 3.2C).
We identified CaMKIIα as a novel mGluR1a/5a second intracellular loop (IL2)
interacting protein, therefore we assessed whether CaMKIIα could be co-precipitated
with a series of purified GST fusions protein corresponding to the IL2 of mGluR5a (Fig.
3.3A). We found that the CaMKIIα could be co-precipitated with the wild-type IL2 of
mGluR5a (Fig. 3.3B). Alanine scanning mutagenesis of the mGluR5a IL2 did not result
in mutations that completely prevented CaMKIIα association with the intracellular loop
domain (Fig. 3.3B and C). However, we found that GFP-CaMKIIα displays reduced
binding to GST-MUT2 compared to the wild type IL2 (Figure 3.3B and C). Interestingly,
this region of mGluR1 was also important for binding to GRK2. More specifically, the
binding site of GRK2 was localized to K691 and K692 (Dhami et al., 2005). We then
tested the co-immunoprecipitation of GFP-CAMKIIα to the full length mGluR1b receptor
and the K691A and K692A mutants within the MUT2 region. We found that these
mutations were not sufficient to block binding to GFP-CAMKIIα (Figure 3.3D and E).
Therefore, it appears that CaMKIIα is not localized to a specific region within the IL2 of
mGluR1.

3.2 Effect of CAMKIIα on mGluR5-mediated signaling in HEK 293 cells
It has been well established that activation of Group I mGluRs turns on Gα/q11
which results in the activation of PLC, IP3 formation and Ca2+ release from intracellular
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Figure 3.2. Localization of CaMKIIα and mGluR5a using confocal microscopy. (A)
Representative confocal microscopy image showing the subcellular localization of GFPCaMKIIα (green) when expressed alone HEK 293 cells. (B) Representative confocal
image demonstrating the localization of FLAG-mGluR5 (red) labelled with Zenon Alexa
Fluor 555-conjugated rabbit anti-FLAG antibody and GFP-CaMKIIα (green). (C)
Representative confocal image demonstrating the internalization of FLAG-mGluR5 (red)
labelled with Zenon Alexa Fluor 555-conjugated rabbit anti-FLAG antibody and GFPCAMKIIα (green) during 20 minutes of stimulation with quisqualate. HEK 293 cells
were transfected with 2 µg of receptor and 0.5 µg of GFP-CaMKIIα plasmid cDNA. Data
are representative of over 20 cells.
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Figure 3.3. CaMKIIα interaction with GST-mGluR1-IL2 mutants.
(A) Schematic representation of the second intracellular loop (IL2) alanine scanning
mutant GST peptides. (B) GST and GST-fusion proteins as labeled were purified from E.
coli recombinant bacteria using Glutathione-Sepharose. Matrix bound GST-fusion
peptides were incubated for 1 hour with lysate from HEK 293 cells overexpressing GFPCaMKIIα and samples were analyzed by Western blotting. Shown is a representative
immunoblot of GST-fusion peptides and associated GFP-CaMKIIα. (C) Quantification of
the amount of recovered GFP-CaMKIIα was normalized to each GST-fusion protein and
expressed as a percentage of GFP-CaMKIIα binding to GST-IL2.

GFP-CaMKIIα

showed reduced binding to GST-MUT2. Data shown are means ± S.E.M of four
independent experiments. (D) Representative immunoblot of immunoprecipitated
mGluR1b and mGluR1b mutants (K691A and K692A) with co-immunoprecipitated
GFP-CaMKIIα. (E) Quantification of co-immunoprecipitated GFP-CaMKIIα analyzed
using Image Lab software. Data shown are means ± S.E.M of three independent
experiments.
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stores (Dhami and Ferguson, 2006). CaMKIIα was previously found to desensitize
mGluR1-mediated IP formation in striatal neurons (Jin et al., 2013a). Therefore, we
examined whether GFP-CaMKIIα overexpression leads to an alteration of FLAGmGluR5-mediated IP formation. Here we employed a mutant FLAG-mGluR5 cDNA
construct that has a single amino acid mutation (A154V) in the glutamate binding region.
This residue is analogous to Ala 168 in mGluR1 which when mutated to valine results in
low basal IP formation, but can respond to agonist stimulation (Esseltine et al., 2012).
Without GFP-CaMKIIα overexpression, we were able to produce a dose-response curve
for quisqualate-induced IP formation with FLAG-mGluR5aA154V. However, we found
that overexpression of GFP-CaMKIIα did not alter mGluR5a-mediated IP formation (Fig.
3.4A). Additionally, we tested whether overexpression of GFP-CaMKIIα had an effect on
mGluR5-mediated Ca2+ release. It has been previously established that activation of
mGluR5 induces Ca2+ oscillations (Kawabata et al., 1999; Dale et al., 2001). We
observed Ca2+ oscillations in HEK 293 cells following activation of mGluR5a with
quisqualate (Fig. 3.5A and B). We found that GFP-CaMKIIα overexpression did not
affect the total amount of mGluR5-mediated Ca2+ release as quantified by area under the
curve (Fig. 3.5C). GFP-CaMKIIα overexpression also did not affect the frequency of
oscillations compared to control cells transfected with GFP despite the trend that there
appears to be a higher frequency of oscillations with GFP- CaMKIIα overexpression (Fig.
3.5D).
In addition to IP3 formation and Ca2+ release, mGluR5 activation leads to the
activation of ERK1/2. Therefore, we tested whether GFP-CaMKIIα overexpression might
alter mGluR5-mediated ERK1/2 phosphorylation in HEK 293 cells. We found that
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Figure 3.4. CaMKIIα does not have a significant effect on mGluR5-mediated inositol
phosphate (IP) formation. (A) Dose response curves for mGluR5-mediated IP
formation in response to treatment with increasing concentrations of quisqualate (0-30
µM) for 30 minutes in cells transfected with 2 µg of plasmid cDNA expressing FLAGmGluR5A154V along with either 0.5 µg of plasmid cDNA expressing GFP-CAMKIIα or
0.5 µg of empty pEGFP vector. (B) Representative immunoblot showing equivalent
FLAG-mGluR5 expression in GFP and

GFP-CaMKIIα transfected cells. The data

represent the mean ± S.E.M of five independent experiments.
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Figure 3.5. CaMKIIα has no affect on mGluR5-mediated Ca2+ release.
Representative traces of the oscillatory Ca2+ response induced by 30 µM quisqualate in
HEK 293 cells transiently transfected with 2 µg of pcDNA3.1 encoding FLAG-mGluR5a
and 0.5 µg of cDNA encoding GFP (A) or GFP-CAMKIIα (B). Cells were imaged to
establish a baseline recording for 1 minute and then stimulated with 30 µM quisqualate
for 5 minutes. (C) Quantification of the Ca2+ concentration represented as area under the
curve (AUC). (D) Quantification of the frequency of oscillations as number of
oscillations in a 5 minute period. Data is presented as mean ± S.E.M for 26-29 cells from
four independent experiments.
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overexpression of GFP-CaMKIIα resulted in a significant decrease in FLAG-mGluR5a
mediated ERK1/2 phosphorylation and following 10 minutes of stimulation with 50 µM
quisqualate this effect was statistically significant. (Fig. 3.6 A and B). Thus, CaMKIIα
overexpression selectively attenuated mGluR5a-mediated ERK1/2 phosphorylation
without affecting IP formation or Ca2+ release.

3.3 Effect of Aβ42 on mGluR5 activity
Several studies have shown that Aβ42 oligomers correlate better with cognitive
impairment and synaptic loss than any other Aβ species (Selkoe, 2006). Current evidence
suggests that the excitatory postsynaptic membrane represents a main target of Aβ
toxicity (Lacor et al., 2007). Aβ oligomers can interact with a variety of cells surface
receptors to modulate their function such as α7-nicotinergic acetylcholine receptor,
NMDA and AMPA receptors, Eph2B and mGluR5 (Snyder et al., 2005; Hsieh et al.,
2006, Cisse et al., 2011; Um et al., 2013). We tested the affect of Aβ42 oligomers on the
interaction between CaMKIIα and mGluR5a. HEK 293 cells overexpressing FLAGmGluR5a and GFP-CaMKIIα were treated with 200 nM Aβ42 oligomers for 0, 2, 5, 15,
and 30 minutes and GFP-CaMKIIα binding to FLAG-mGluR5a was assessed by coimmunoprecipitation. We found that treatment with 200 nM Aβ42 oligomers increases
the amount of GFP-CaMKIIα co-immunoprecipitated with mGluR5a over time and
produced a significant increase in CaMKII co-immunoprecipitated with mGluR5a
following 15 minutes of stimulation (Fig. 3.7A and B). Thus, Aβ42 oligomers can alter
the association between mGluR5 and CaMKIIα. Aβ42 oligomers have been shown to
induce mGluR5a-mediated Ca2+ release (Um et al., 2013). However whether Aβ42
42

Figure 3.6.

CAMKIIα overexpression significantly decreases mGluR5-mediated

ERK1/2 phosphorylation. HEK 293 cells were transiently transfected with 2 µg of
pcDNA3.1 encoding FLAG-mGluR5a and 0.5 µg cDNA expressing GFP-CaMKIIα or
pEGFP vector as labeled. Cells were stimulated with 50 µM quisqualate for the indicated
time points. (A) Representative immunoblot of FLAG-mGluR5a, GFP-CaMKIIα,
Phospho-ERK1/2 and Total-ERK1/2. (B) Quantification of

phosphorylated ERK1/2

compared to total ERK1/2 as fold-increase over basal. GFP-CAMKIIα significantly
decreased ERK1/2 phosphorylation during 10 minutes of quisqualate stimulation as
analyzed by Student’s two-tailed t-test. *p<0.05. Data are mean ± S.E.M of five
independent experiments.
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Figure 3.7.

Αβ42

oligomers increase the amount of co-immunoprecipitated

CAMKIIα to mGluR5a. HEK 293 cells were transiently transfected with 2 µg of
pcDNA3.1 encoding FLAG-mGluR5a and 0.5 µg cDNA encoding GFP-CaMKIIα as
labelled. Cells were treated with 200 nM Αβ42 oligomers for the indicated time points.
(A) Shown is a representative immunoblot for immunoprecipitated FLAG-mGluR5a, coimmunoprecipitated GFP-CaMKIIα, and GFP-CaMKIIα inputs. (B) Quantification of coimmunoprecipitated GFP-CaMKIIα was done using Image Lab software. Treatment with
Αβ42 oligomers

for

15

minutes

significantly

increases

the

amount

of

co-

immunoprecipitated GFP-CaMKIIα compared to untreated control. *p< 0.05. Data is
presented as mean ± S.E.M fold increase over untreated control of five independent
experiments.
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oligomers can activate mGluR5a-mediated ERK1/2 phosphorylation was unknown.
Therefore, we tested whether Aβ42 oligomers (100 nM) could activate ERK1/2
phosphorylation in HEK 293 cells overexpressing FLAG-mGluR5a. We found that
treatment with Aβ42 oligomers for 5 minutes results in over 2-fold increase in ERK1/2
phosphorylation and over 4-fold increase with 10 minutes of stimulation in cells
overexpressing FLAG-mGluR5a (Fig. 3.8A and B). Cells that were not transfected with
the receptor did respond to Aβ42 oligomer treatment (Fig. 3.8A and B). In addition, it
was found that overexpression of GFP-CaMKIIα did not impair the ERK1/2
phosphorylation induced by Aβ42 oligomers when compared to control cells expressing
GFP (Fig.3.8A and B) suggesting that

Aβ42 oligomers can differentially regulate

mGluR5a-mediated ERK1/2 signaling.
ERK1/2 activation following Group I mGluR activation can occur through a
variety of mechanisms as previously discussed in Chapter 1.2.4. Therefore, we tested
whether Aβ42-mediated ERK1/2 activation occurred via a PKC-dependent mechanism.
HEK293 cells were incubated in HBSS with DMSO (vehicle) or the PKC inhibitor
bisindolymaleimide I (Bis-1) prior to stimulation with 30 µΜ quisqualate or 100 nM
Aβ42 oligomers for 5 minutes and ERK1/2 phosphorylation was assessed. We found that
PKC

inhibition

significantly

reduced

FLAG-mGluR5a

mediated

ERK1/2

phosphorylation induced by both quisqualate and Aβ42 oligomers (Figure 3.9A and B).
Thus Aβ42-mediated ERK1/2 activation was PKC-dependent.
Αβ42 oligomers were shown to interact with PrPC with high affinity and this
complex could interact with mGluR5 to mediate signaling (Um et al., 2013). Using
confocal microscopy we determined the effect of PrPC and mGluR5a co-expression on
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Figure

3.8.

Aβ42

oligomers

can

activate

mGluR5a-mediated

ERK1/2

phosphorylation. HEK 293 cells were transiently transfected with 2 µg of pcDNA3.1
encoding FLAG-mGluR5 and 0.5 µg cDNA and pEGFP encoding CaMKIIα or pEGFP as
labelled. Cells were stimulated with 100 nM Αβ42 oligomers for the indicated time
points. (A) Representative immunoblot of FLAG-mGluR5, Phospho-ERK1/2 and TotalERK1/2. (B) Quantification of phosphorylated ERK1/2 compared to total ERK1/2 as
fold over basal. CaMKIIα has no significant effect on the mGluR5a-mediated ERK1/2
phosphorylation induced by 100 nM Αβ42 oligomers p>0.05. Data are mean ± S.E.M of
four independent experiments.
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Figure 3.9. Αβ42 mediated ERK1/2 activation is PKC-dependent. HEK 293 cells
were transiently transfected with 2 µg of pcDNA3.1 encoding FLAG-mGluR5 and
stimulated with 30 µM quisqualate or 100 nM Αβ42 oligomers in the absence or presence
of 1 µM bisindolymaleimide I (Bis-1). (A) Representative immunoblot of
mGluR5, phospho-ERK1/2 and total-ERK1/2. (B) Quantification of

FLAG-

phosphorylated

ERK1/2 compared to total ERK1/2 as fold over basal. PKC inhibition with Bis-1
significantly

reduces

mGluR5a-mediated

ERK1/2

phosphorylation

induced

by

quisqualate and Αβ42 oligomers *p<0.05. The data represent the mean ± S.E.M of seven
independent experiments
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CaMKIIα distribution. We found that cells co-expressing these cell surface proteins
showed a higher percentage of redistribution of GFP-CAMKIIα into punctuate clusters
(Fig.3.10A) compared to cells expressing PrPC and mGluR5 individually. This effect did
not occur in cells transfected with empty GFP vector. (Figure 3.10B). This suggests that
CaMKIIα distribution may be affected by the mGluR5-PrPC interactions.
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Figure 3.10. PrPC overexpression results in redistribution of subcellular GFPCaMKIIα. HEK 293 cells were transiently transfected with 2 µg of pcDNA3.1 encoding
FLAG-mGluR5a, 2 µg of pcDNA3.1 encoding PrPC and 0.5 µg of GFP-CaMKIIα or
empty pEGFP vector (control). Representative confocal microscopy images showing cell
surface FLAG-mGluR5a (red) labelled with Zenon Alexa Fluor 647-conjugated rabbit
FLAG antibody, PrPC (blue) labelled with Zenon Alexa Fluor 555-conjugated mouse
PrPC antibody

and GFP-CaMKIIα (A) or empty pEGFP vector (B). Data are

representative of over 70 cells for each transfection.
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CHAPTER 4
DISCUSSION
The excitatory neurotransmitter glutamate mediates many physiological processes
in the central nervous system through ionotropic and metabotropic glutamate receptors
(Ozawa et al., 1998; Nakanishi, 1992). The Group I mGluRs play a key role in neuronal
development, learning and synaptic transmission (Bordi and Ugolini, 1999; Nakanishi
and Masu, 1994). Additionally, these receptors also have been implicated in a number of
neurodegenerative diseases such as amyotrophic lateral sclerosis, Huntington’s and
Alzheimer’s disease (Ribeiro et al., 2010a). Regulation of these receptors is a dynamic
process involving many interacting proteins and scaffolding complexes (Enz, 2012). We
have identified CaMKIIα as a novel IL2-interacting protein of Group I mGluRs. Our
results reveal the following: 1) the interaction between CaMKIIα and mGluR5 is
independent of CaMKIIα activity 2) CaMKIIα decreases mGluR5-mediated ERK1/2
phosphorylation, but not IP3 formation or Ca2+ release, 3) CaMKIIα binding to mGluR5
is increased in the presence of Aβ42 oligomers, and 4) Aβ42 oligomers can activate
mGluR5-mediated ERK1/2 in a PKC dependent manner.
4.1 CAMKIIα interacts with mGluR5 independent of CAMKIIα activity.
Compared to prototypic GPCRs, the Group I mGluRs have small intracellular
loops and a large C-tail which harbours many interacting proteins (Enz, 2012).
Interestingly, C-tail interacting proteins such as GRK2, Pyk2 and CAIN can also interact
with the second intracellular loop (Dhami et al., 2005; Nicodemo et al., 2010; Ferreira et
al., 2009). This ability may result in differential outcomes in the regulation of these
receptors. For example, the mGluR1a and mGluR1b splice variants reveal subtle
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differences the attenuation of mGluR1 signaling by GRK2 (Dhami et al., 2005).
In a proteomic screen, we have identified CaMKIIα as a novel IL2 interacting
protein of Group I mGluRs. The IL2 is also able to interact with the other CNS abundant
CaMKII isoform, CaMKIIβ. Τhe association between CaMKIIα and Group I mGluRs
appears to be a direct interaction, since we have shown that the second intracellular loop
peptide is sufficient for this interaction to occur. Additionally, CaMKIIα has been shown
to interact with mGluR1 through the C-terminus tail demonstrating once more that
interacting proteins of Group I mGluRs have multiple sites for interaction (Jin et al.,
2013a). More specifically, this group found that CaMKIIα interacts with the proximal Ctail of mGluR1a and the interaction is localized between the residues K841 and N885 (Jin
et al., 2013a). As a serine/threonine kinase, many binding partners of CaMKIIα are
phosphorylation substrates. The region in mGluR1a that mediates CaMKIIα binding
contains the CaMKIIα substrate recognition motif, RXXT (Jin et al., 2013a; White et al.,
1998) and can be phosphorylated by CaMKIIα. mGluR5 also contains several CaMKII
substrate recognition motifs. However whether they are phosphorylated by CaMKIIα is
unknown. Therefore, future experiments are needed to determine if CaMKIIα
phosphorylates mGluR5 and whether phosphorylation by CaMKIIα contributes to
receptor regulation.
Another important characteristic of the interaction between mGluR5 and
CaMKIIα is whether mGluR5 can bind to the activated form of CaMKIIα. Jin et al.,
(2013a) showed using in vitro assays that the presence of Ca2+ activates CaMKIIα and
activated CaMKIIα has a higher affinity for mGluR1 as it displays greater binding to the
receptor than the inactivated form. In addition, activated CaMKIIα has been shown to
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increase the affinity for many targets including the D3 dopamine receptor and M4
muscarinic receptor (Liu et al., 2010; Guo et al., 2011). Moreover, the activation of
CaMKIIα results in translocation from the cytoplasm to the post-synaptic density where it
binds to the NMDA receptor and facilitates LTP (Strack et al., 1997). Thus, activation of
CaMKIIα represents an important mechanism by which the kinase can regulate its
association with binding partners. In contrast to these studies, we found that treatment
with the CAMKIIα inhibitor KN-93 does not result in any difference in the amount of
CaMKIIα co-immunoprecipitated with mGluR5a. This, along with the result that the
interaction between CaMKIIα mGluR5 is independent of receptor activation, indicates
that the association between CaMKIIα and mGluR5 is independent of CaMKIIα activity.
When two molecules of Ca2+/CaM bind to two subunits of CaMKIIα,
autophosphorylation of the enzyme can occur. CaMKIIα autophosphorylation results in
persistent activity of CaMKIIα even after Ca2+/CaM is no longer bound (Hanson and
Schulman, 1992). The inhibitor KN-93 works by interacting with the Ca2+/CaM binding
site on CaMKIIα to prevent its activation by Ca2+/CaM. However, this inhibitor does not
prevent

autophosphorylation

of

the

kinase

(Sumi

et

al.,

1991).

CaMKIIα

autophosphorylation has been shown to lead to increased binding to the D3 dopamine
receptor (Liu et al., 2010). It would be interesting to see whether autophosphorylated
CaMKIIα interacts with mGluR5 and whether autophosphorylation of CaMKIIα
contributes in the regulation of mGluR5.

4.2 Regulation of mGluR5 signaling by CaMKIIα
Interacting proteins of Group I mGluRs can be categorized according to the roles
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they play such as scaffolding, cytoskeletal regulation and signaling. In the present study,
we looked at the effects of CaMKIIα on mGluR5 signaling. It is well established that
activation of Group I mGluRs activates the heterotrimeric Gαq/11 protein which leads to
formation of IP3 and Ca2+ release from intracellular stores. Jin and coworkers (2013a)
established a role for CaMKIIα in regulating mGluR1-mediated IP formation in rat
striatal slices. They found that blocking the interaction between mGluR5 and CaMKIIα
by a Tat interference peptide results in a reduced desensitization response to DHPG. We
previously showed that overexpression of CAMKIIα in HEK293 cells does not affect
mGluR1a-mediated IP formation. However, this difference may be attributed to the
differences between HEK293 cells and rat striatal neurons. In this study, we show that
overexpression of CaMKIIα has no effect on mGluR5-mediated IP formation, but
whether this occurs in neurons is unknown and represents an area for future study.
When looking at Ca2+ signaling, we observed no significant effect of CaMKIIa on
mGluR5-mediated Ca2+ release despite the tendency for Ca2+ release and the frequency of
Ca2+ oscillations to be increased in the presence of CaMKIIα. The number of Ca2+
oscillations is shown to be affected by the amount of cell surface receptor (Nash et al.,
2002; Choi et al., 2011). A study in Chinese Hamster Ovary cells comparing the ability of
receptor density and agonist concentration to affect mGluR5-mediated Ca2+ oscillations
found that Ca2+ oscillation frequency is affected by receptor density and not agonist
concentration (Nash et al., 2002). In support of this, mGluR5 induced Ca2+ oscillations
are to be affected by CaM, an interacting protein that affects cell surface expression of
mGluR5 (Choi et al., 2011). This group found that a mutant form of mGluR5 that
disrupts CaM binding results in reduced cell surface expression, as well as reduced
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frequency of Ca2+ oscillations. We have previously established that mGluR1 cell surface
expression is unaffected by CaMKIIα. However, whether CaMKIIα affects mGluR5 cell
surface expression is unknown. It is likely, that CaMKIIα has no effect on mGluR5 cell
surface expression since both IP and Ca2+ seem to be unaffected CaMKIIα.
As previously mentioned, Group I mGluRs can also activate the ERK1/2
signaling cascade by a variety of mechanisms. CaMKII has been shown to affect DHPGmediated ERK phosphorylation in striatal neurons (Choe and Wang, 2001). They found
that treatment with the CaMKII inhibitor, KN-62, results in attenuation of DHPGinduced ERK phosphorylation in the rat striatum. DHPG can activate both mGluR1 and
mGluR5, however this study did not determine the relative contribution of ERK
phosphorylation caused by each receptor. We found that overexpression of CaMKIIα
results in the attenuation of mGluR5-mediated ERK1/2 phosphorylation without affecting
IP formation or Ca2+ release. This indicates that the regulation of mGluR5 by CaMKIIα
may involve the participation of scaffolding proteins that selectively couple the receptor
to distinct signaling pathways. This is similar to the effect produced by biased GPCRs
ligands that activate select downstream signaling pathways (Luttrell and Kenakin, 2011).

4.3 Regulation of mGluR5 by Aβ oligomers
Soluble Aβ is a key player in the early pathogenesis of Alzheimer’s disease. One
of the proposed mechanisms of Aβ-mediated toxicity involves the disturbance of Ca2+
homeostasis (Khachaturian ZS, 1989; Green et al., 2009; Berridge MJ, 2010). Aβ has
been shown to affect Ca2+ signaling in a manner dependent on mGluR5 (Renner et al.,
2010; Grolla et al., 2013, Um et al., 2013). In hippocampal astrocytes, Aβ oligomer
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treatment increases DHPG-mediated Ca2+ release (Grolla et al., 2013). Aβ oligomers can
act as extracellular scaffolds of mGluR5 to reduce mobility and induce clustering of the
receptor. This effect as well as mimicking clustering by artificial cross-linking leads to
increased Ca2+ signaling in hippocampal neurons (Renner et al., 2010). Additionally,
Aβ induced mGluR5-mediated Ca2+ signaling has been found by Um and coworkers
(2013) to occur in a manner that is dependent on PrPC.
In addition to inducing Ca2+ release, Aβ signaling can also lead to ERK1/2
activation. Chong et al., (2006) found that ERK1/2 can be activated by Aβ oligomers in a
time and dose-dependent manner in rat hippocampal slices. Aβ oligomer-mediated
ERK1/2 activation can also occur in SH-SY5Y cells via the α-7 nicotinic acetylcholine
receptor (Young et al., 2009). We show that ERK1/2 activation can occur in HEK293
cells transfected with mGluR5 in response to stimulation with 100 nM Aβ42 oligomers.
Furthermore, we found that treating cells with a PKC inhibitor prevented the ERK1/2
activation induced by Aβ42 oligomers suggesting that Aβ42 oligomer-induced ERK1/2
activation is PKC-dependent. The role of ERK1/2 activation in Alzheimer’s disease is
unclear. Some studies implicate ERK1/2 in the hyperphosphorylation of tau, a major
hallmark of Alzheimer’s disease, but this involvement is still controversial (Drewes et al.,
1992; Ledesma et al., 1992; Lu et al., 1993; Pei et al., 2002). Additionally, we found that
CaMKIIα overexpression does not have any appreciable effect on Aβ induced ERK1/2
activation as it did by conventional mGluR5 activation with quisqualate. This indicates
that Aβ oligomers can differentially regulate mGluR5 signaling: while CaMKIIα appears
to affect agonist-induced mGluR5 signaling, it does not appear to affect Aβ42 induced
signaling (Summarized in Figure 4.1).
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We also show that the presence of Aβ42 oligomers results in increased binding of
CaMKIIα to mGluR5. As previously mentioned Aβ42 oligomers act as an extracellular
scaffold for mGluR5 and thus can cause clustering of mGluR5 and reduce receptor
mobility similar to that of artificially cross-linking the receptor (Renner et al., 2010). It is
possible that the clustering of mGluR5 induced by Aβ42 oligomers can stabilize the
interaction with CaMKIIα, thus leading to increased co-immunoprecipitated CAMKIIα to
the receptor. To test this hypothesis, we could examine whether artificially cross-linking
the receptor produces an increase in co-immunoprecipitated CaMKIIα with mGluR5.
Interestingly, receptor cross-linking is a necessary step in the co-immunoprecipitation of
some GPCR interacting proteins (Hall RA, 2004). Both Aβ42 oligomers and mGluR5 are
involved in the pathogenesis of Alzheimer’s disease (Selkoe, 2006; Hamilton et al.,
2014). The regulation of mGluR5 by Aβ42 oligomers represents an area of future study
in understanding how these two players contribute to the pathogenesis of Alzheimer’s
disease.

4.4 Role of CAMKIIα and mGluR5 in synaptic plasticity
LTP and LTD are well established forms of synaptic plasticity underlying
memory and learning processes (Malenka and Bear, 2004). As previously mentioned,
translocation of activated CaMKIIα to the PSD and binding to the NMDA receptor is
important for LTP induction (Shen and Meyer, 1999). Additionally, NMDA dependent
LTP in the CA1 region of the hippocampus is shown to involve mGluR5 and several
studies indicate that mGluR5 is involved in late phase LTP, a form of synaptic plasticity
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Figure 4.1 Schematic model of mGluR5 signaling. mGluR5 activation results in
activation of PLC, IP3 formation, Ca2+ release from intracelluar stores and PKC
activation followed by ERK1/2 phosphorylation. mGluR5 acts as an extracellular
scaffold for the Aβ oligomer-PrPC complex which allows for intracellular Ca2+ signaling.
Ca2+ can activate PKC leading to ERK1/2 phosphorylation. We show that
Aβ42 oligomers can activate mGluR5-dependent ERK1/2 phosphorylation in a PKCdependent manner. CaMKIIα interacts with mGluR5 to attenuate agonist-stimulated
ERK1/2 phosphorylation but not Aβ42−stimulated ERK1/2 phosphorylation however the
exact mechanisms are unknown.
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dependent on protein synthesis (Lu et al., 1997, Fransesconi et al., 2004). Both CaMKIIα
and mGluR5 play an important role in LTP however how the interaction between
CaMKIIα and mGluR5 plays a role in LTP is unknown and would be a key future area of
study. Interestingly, mGluR5-dependent LTD may be attenuated by activation of CaMKII
(Huang et al., 2013). This study showed that CaMKIIα activation resulted in the
phosphorylation of Homer1b/c, thus impairing its interaction with mGluR5.
Consequently, the disruption of this interaction attenuates mGluR5-mediated LTD
(Huang et al., 2013). A direct role for CaMKIIα on mGluR5-dependent potentiation of
NMDA receptors has been proposed by (Jin et al., 2013b). In this study, mGluR5mediated Ca2+ release results in the dissociation of C-tail bound CaMKIIα and
recruitment to the NMDA receptor where it can phosphorylate the NR2B subunit, thereby
possibly effecting LTP (Jin et al., 2013b).

4.5 Summary
In summary, we have shown here that CaMKIIα can associate with mGluR5
independent of CaMKIIα activity. We demonstrated that CaMKIIα attenuates mGluR5mediated ERK1/2 phosphorylation in the absence of attenuated mGluR5-mediated IP3
formation and Ca2+ release. Furthermore, we report that Aβ oligomers can increase
binding of CaMKIIα to mGluR5 and can activate mGluR5-mediated ERK1/2
phosphorylation. Group I mGluRs are not only important for learning and memory but
also for their contribution to neurodegenerative diseases. Therefore, understanding the
mechanisms by which Group I mGluRs can be regulated can provide us with novel
therapeutic targets to treat neurodegenerative diseases.
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